Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.

Abstract

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. Here we discuss the clinical trial results of vedolizumab (anti-α4β7, LDP-02, MLN-02, and MLN0002) and its impact on future management of inflammatory bowel disease.

• Authors: Niklas Krupka, Daniel C Baumgart
• Journal: Drug design, development and therapy (Drug Des Devel Ther) Vol. 9 Pg. 147-54 ( 2015) ISSN: 1177-8881 [Electronic] New Zealand
• PMID: 25552903 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• Tumor Necrosis Factor-alpha
• vedolizumab

Topics

• Animals
• Antibodies, Monoclonal, Humanized (chemistry, pharmacology, therapeutic use)
• Cell Movement (drug effects)
• Drug Design
• Gastrointestinal Agents (chemistry, pharmacology, therapeutic use)
• Humans
• Inflammatory Bowel Diseases (drug therapy)
• Leukocytes (drug effects)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)